BRCC45 Antibody
| Code | Size | Price |
|---|
| PSI-4329-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-4329-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
BRCC45 Antibody: BRCC4, BRCC45, BRCA1-A complex subunit BRE, Brain and reproductive organ-expressed protein
Application Note:
BRCC45 antibody can be used for detection of BRCC45 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
BRCC45 Antibody: BRCC45 was initially suggested to be a housekeeping protein that is highly expressed in brain and reproductive organs. Later experiments indicated BRCC45 forms a complex with the breast and ovarian predisposition proteins BRCA1 and BRCA2 as well as RAD51 and BRCC36. This complex has a ubiquitin E3 ligase activity and is thought to enhance cellular survival following DNA damage. BRCC45 has also been suggested to function as a death receptor-associated anti-apoptotic protein by inhibiting the BID-induced activation of the mitochondrial apoptotic pathway. Higher levels of BRCC45 were detected in the majority of hepatocellular carcinomas, suggesting that BRCC45 may promote tumorigenesis when overexpressed. At least three isoforms of BRCC45 are known to exist.
Background References:
- Li L, Yoo H, Beckker FF, et al. Identification of a brain- and reproductive-organs-specific gene responsive to DNA damage and retinoic expression. Biochim. Biophys. Res. Commun.1995; 206:764-74.
- Dong Y, Hakimi MA, Chen X, et al. Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalsome-like subunit and its role in DNA repair. Mol. Cell2003; 12:1087-99.
- Li Q, Ching AK, Chan BC, et al. A death receptor-associated anti-apoptotic protein, BRE, inhibits mitochondrial apoptotic pathway. J. Biol. Chem.2004; 279:52106-16.
- Chan BC, Ching AK, To KF, et al. BRE is an antiapoptotic protein in vivo and overexpressed in human hepatocellular carcinoma. Oncogene2007; epub.
Buffer:
BRCC45 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Bovine: (100%), Chicken: (100%)
Immunogen:
BRCC45 antibody was raised against a 18 amino acid synthetic peptide from near the amino terminus of human BRCC45.
The immunogen is located within the last 50 amino acids of BRCC45.
The immunogen is located within the last 50 amino acids of BRCC45.
NCBI Gene ID #:
9577
NCBI Official Name:
brain and reproductive organ-expressed (TNFRSF1A modulator)
NCBI Official Symbol:
BRE
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_004890
Protein GI Number:
21361171
Purification:
BRCC45 Antibody is affinity chromatography purified via peptide column.
Research Area:
Homeostasis,Cancer
Swissprot #:
Q9NXR7
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | BRCC45 Peptide | PSI-4329P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|